121 related articles for article (PubMed ID: 8943690)
1. EO9 phase II study in advanced breast, gastric, pancreatic and colorectal carcinoma by the EORTC Early Clinical Studies Group.
Dirix LY; Tonnesen F; Cassidy J; Epelbaum R; ten Bokkel Huinink WW; Pavlidis N; Sorio R; Gamucci T; Wolff I; Te Velde A; Lan J; Verweij J
Eur J Cancer; 1996 Oct; 32A(11):2019-22. PubMed ID: 8943690
[TBL] [Abstract][Full Text] [Related]
2. Phase I trial with weekly EO9, a novel bioreductive alkylating indoloquinone, by the EORTC Early Clinical Study Group (ECSG).
Aamdal S; Lund B; Koier I; Houten M; Wanders J; Verweij J
Cancer Chemother Pharmacol; 2000; 45(1):85-8. PubMed ID: 10647507
[TBL] [Abstract][Full Text] [Related]
3. Clinical studies with EO9, a new indoloquinone bioreductive alkylating cytotoxic agent. EORTC Early Clinical Trials Group.
Verweij J; Aamdal S; Schellens J; Koier I; Lund B
Oncol Res; 1994; 6(10-11):519-23. PubMed ID: 7620220
[TBL] [Abstract][Full Text] [Related]
4. A randomized phase II study with two schedules of the novel indoloquinone EO9 in non-small-cell lung cancer: a study of the EORTC Early Clinical Studies Group (ECSG).
Pavlidis N; Hanauske AR; Gamucci T; Smyth J; Lehnert M; te Velde A; Lan J; Verweij J
Ann Oncol; 1996 Jul; 7(5):529-31. PubMed ID: 8839911
[TBL] [Abstract][Full Text] [Related]
5. EO9: a novel bioreductive alkylating indoloquinone with preferential solid tumour activity and lack of bone marrow toxicity in preclinical models.
Hendriks HR; Pizao PE; Berger DP; Kooistra KL; Bibby MC; Boven E; Dreef-van der Meulen HC; Henrar RE; Fiebig HH; Double JA
Eur J Cancer; 1993; 29A(6):897-906. PubMed ID: 8484984
[TBL] [Abstract][Full Text] [Related]
6. Phase I and pharmacologic study of the novel indoloquinone bioreductive alkylating cytotoxic drug E09.
Schellens JH; Planting AS; van Acker BA; Loos WJ; de Boer-Dennert M; van der Burg ME; Koier I; Krediet RT; Stoter G; Verweij J
J Natl Cancer Inst; 1994 Jun; 86(12):906-12. PubMed ID: 8196081
[TBL] [Abstract][Full Text] [Related]
7. Phase I pharmacokinetics and limited sampling strategies for the bioreductive alkylating drug EO9. EORTC Early Clinical Trials Group.
McLeod HL; Graham MA; Aamdal S; Setanoians A; Groot Y; Lund B
Eur J Cancer; 1996 Aug; 32A(9):1518-22. PubMed ID: 8911111
[TBL] [Abstract][Full Text] [Related]
8. Potentiation of EO9 anti-tumour activity by hydralazine.
Bibby MC; Sleigh NR; Loadman PM; Double JA
Eur J Cancer; 1993; 29A(7):1033-5. PubMed ID: 8499134
[TBL] [Abstract][Full Text] [Related]
9. Carzelesin phase II study in advanced breast, ovarian, colorectal, gastric, head and neck cancer, non-Hodgkin's lymphoma and malignant melanoma: a study of the EORTC early clinical studies group (ECSG).
Pavlidis N; Aamdal S; Awada A; Calvert H; Fumoleau P; Sorio R; Punt C; Verweij J; van Oosterom A; Morant R; Wanders J; Hanauske AR
Cancer Chemother Pharmacol; 2000; 46(2):167-71. PubMed ID: 10972487
[TBL] [Abstract][Full Text] [Related]
10. EO9: relationship between DT-diaphorase levels and response in vitro and in vivo.
Collard J; Matthew AM; Double JA; Bibby MC
Br J Cancer; 1995 Jun; 71(6):1199-203. PubMed ID: 7779711
[TBL] [Abstract][Full Text] [Related]
11. Factors affecting sensitivity to EO9 in rodent and human tumour cells in vitro: DT-diaphorase activity and hypoxia.
Robertson N; Haigh A; Adams GE; Stratford IJ
Eur J Cancer; 1994; 30A(7):1013-9. PubMed ID: 7946565
[TBL] [Abstract][Full Text] [Related]
12. DT-diaphorase activity correlates with sensitivity to the indoloquinone EO9 in mouse and human colon carcinomas.
Walton MI; Bibby MC; Double JA; Plumb JA; Workman P
Eur J Cancer; 1992; 28A(10):1597-600. PubMed ID: 1389472
[TBL] [Abstract][Full Text] [Related]
13. Unusually marked hypoxic sensitization to indoloquinone EO9 and mitomycin C in a human colon-tumour cell line that lacks DT-diaphorase activity.
Plumb JA; Workman P
Int J Cancer; 1994 Jan; 56(1):134-9. PubMed ID: 8262670
[TBL] [Abstract][Full Text] [Related]
14. Development, pharmacology, role of DT-diaphorase and prospects of the indoloquinone EO9.
Smitskamp-Wilms E; Hendriks HR; Peters GJ
Gen Pharmacol; 1996 Apr; 27(3):421-9. PubMed ID: 8723519
[TBL] [Abstract][Full Text] [Related]
15. Pharmacological properties of a new aziridinylbenzoquinone, RH1 (2,5-diaziridinyl-3-(hydroxymethyl)-6-methyl-1,4-benzoquinone), in mice.
Loadman PM; Phillips RM; Lim LE; Bibby MC
Biochem Pharmacol; 2000 Apr; 59(7):831-7. PubMed ID: 10718341
[TBL] [Abstract][Full Text] [Related]
16. A novel strategy for NQO1 (NAD(P)H:quinone oxidoreductase, EC 1.6.99.2) mediated therapy of bladder cancer based on the pharmacological properties of EO9.
Choudry GA; Stewart PA; Double JA; Krul MR; Naylor B; Flannigan GM; Shah TK; Brown JE; Phillips RM
Br J Cancer; 2001 Oct; 85(8):1137-46. PubMed ID: 11710826
[TBL] [Abstract][Full Text] [Related]
17. Enhancement of interstitial photodynamic therapy by mitomycin C and EO9 in a mouse tumour model.
Baas P; Michielsen C; Oppelaar H; van Zandwijk N; Stewart FA
Int J Cancer; 1994 Mar; 56(6):880-5. PubMed ID: 8119776
[TBL] [Abstract][Full Text] [Related]
18. Bioreductive agents: a clinical update.
Boyer MJ
Oncol Res; 1997; 9(6-7):391-5. PubMed ID: 9406245
[TBL] [Abstract][Full Text] [Related]
19. Phase II evaluation of diaziquone in gastric and pancreatic cancers. A Southeastern Cancer Study Group Trial.
DeSimone P; Kramer B; Omura GA; Bartolucci AA
Am J Clin Oncol; 1986 Oct; 9(5):401-2. PubMed ID: 3776902
[TBL] [Abstract][Full Text] [Related]
20. Multicenter phase II study of brequinar sodium in patients with advanced gastrointestinal cancer.
Moore M; Maroun J; Robert F; Natale R; Neidhart J; Dallaire B; Sisk R; Gyves J
Invest New Drugs; 1993 Feb; 11(1):61-5. PubMed ID: 8349438
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
